Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism

American Journal of the Medical Sciences

Volumn 335, Issue 2, 2008, Pages 105-110

  Selektor, Yelena ^a   Ahokas, Robert A ^a   Bhattacharya, Syamal K ^a   Sun, Yao ^a   Gerling, Ivan C ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aldosteronism; Calcium overloading; Cinacalcet; Oxidative stress; Secondary hyperparathyroidism

Indexed keywords

ALDOSTERONE; ALPHA 1 ANTITRYPSIN; CALCIUM; CINACALCET; MALONALDEHYDE; PARATHYROID HORMONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HEART MUSCLE; HYPERALDOSTERONISM; HYPERPARATHYROIDISM; MALE; NONHUMAN; OXIDATIVE STRESS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PERIPHERAL BLOOD MONONUCLEAR CELL; RAT;

EID: 39149109601     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318134f013     Document Type: Article

References (47)

1. Swedberg K, Eneroth P, Kjekshus J. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
2. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
3. Villarreal D, Freeman RH, Johnson RA. Neurohormonal modulators and sodium balance in experimental heart failure. Am J Physiol 1993;264:H1187-93.
4. Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin: studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305.
5. Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002;106:92-9.
6. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994;96:35-41.
7. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
8. Khouzam RN, Dishmon DA, Farah V, et al. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006;331:30-4.
9. LaGuardia SP, Dockery BK, Bhattacharya SK, et al. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci 2006;332:112-8.
10. Chen L, Zang Y, Bai B, et al. Electron spin resonance determination and superoxide dismutase activity in polymorphonuclear leukocytes in congestive heart failure. Can J Cardiol 1992;8:756-60.
11. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, et al. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996;131:146-52.
12. Sawyer DB, Siwik DA, Xiao L, et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-88.
13. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285:H813-21.
14. 2 in peripheral blood mononuclear cells. Circulation 2005;111:51-7.
15. Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res 2003;93:e124-35.
16. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004;287:H2023-6.
17. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005;111:871-8.
18. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990;67:1355-64.
19. Goodwin KD, Ahokas RA, Bhattacharya SK, et al. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci 2006;332:73-8.
20. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994;14:219-31.
21. Vidal A, Sun Y, Bhattacharya SK, et al. The calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 2006;290:H286-94.
22. Quarles LD. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues. Curr Opin Nephrol Hypertens 2003;12:349-55.
23. Chen RA, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004;286:F1005-11.
24. 3 but not cinacalcet HCl (Sensipar®/Mimpara®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1370-7.
25. Wada M, Ishii H, Furuya Y, et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998;53:448-53.
26. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
27. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
28. Fox J, Lowe SH, Conklin RL, et al. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 1999;10:97-103.
29. Deshmukh PA, Kamalov G, Bhattacharya SK. Cytosolic calcium and zinc in cardiomyocytes of rats with aldosteronism: response to spironolactone and amlodipine cotreatment [abstract]. J Invest Med 2007;55(Suppl 1):S280.
30. Kamalov G, Deshmukh PA, Bhattacharya SK. Cytosolic and mitochondrial calcium in rat cardiomyocytes: response to aldosteronism and cotreatment with spironolactone or amlodipine [abstract]. J Invest Med 2007;55(Suppl 1):S255.
31. Wang R, Xu C, Zhao W, et al. Calcium and polyamine regulated calcium-sensing receptors in cardiac tissues. Eur J Biochem 2003;270:2680-8.
32. Tfelt-Hansen J, Hansen JL, Smajilovic S, et al. Calcium receptor is functionally expressed in rat neonatal ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol 2006;290:H1165-71.
33. Sun YH, Liu MN, Li H, et al. Calcium-sensing receptor induces rat neonatal ventricular cardiomyocyte apoptosis. Biochem Biophys Res Commun 2006;350:942-8.
34. Zhang WH, Fu SB, Lu FH, et al. Involvement of calcium-sensing receptor in ischemia/reperfusion-induced apoptosis in rat cardiomyocytes. Biochem Biophys Res Commun 2006;347:872-81.
35. Cesselli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001;89:279-86.
36. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6.
37. Miyamoto M, Kishimoto C, Shioji K, et al. Cutaneous arteriolar thioredoxin expression in patients with heart failure. Circ J 2003;67:116-8.
38. Tsutsui H, Ide T, Hayashidani S, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001;104:134-6.
39. Aukrust P, Ueland T, Müller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
40. Damås JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure: modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001;38:187-93.
41. Yndestad A, Damås JK, Eiken HG, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002;54:175-82.
42. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
43. Anker SD, Clark AL, Teixeira MM, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999;83:612-5.
44. Silver MA. Dietary research in heart failure: beyond the salt shaker. J Am Coll Cardiol 2003;42:1224-5.
45. Brink M, Price SR, Chrast J, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001;142:1489-96.
46. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007;73:298-309.
47. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.